Malta - English - Medicines Authority

sigillata limited (ireland) inniscarra, main street, rathcoole, co. dublin d24 e029 , ireland - granisetron hydrochloride - film-coated tablet - granisetron hydrochloride 1 mg - antiemetics and antinauseants

Malta - English - Medicines Authority

sigillata limited (ireland) inniscarra, main street, rathcoole, co. dublin d24 e029 , ireland - granisetron hydrochloride - film-coated tablet - granisetron hydrochloride 2 mg - antiemetics and antinauseants

Canada - English - Health Canada

jamp pharma corporation - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - granisetron hydrochloride - concentrate for solution for injection - 3mg/3ml - serotonin (5ht3) antagonists; granisetron

Canada - English - Health Canada

apotex inc - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

United States - English - NLM (National Library of Medicine)

wockhardt limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 0.1 mg in 1 ml - - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. chemotherapy-induced nausea and vomiting [see dosage and administration (2)]  for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established.

United States - English - NLM (National Library of Medicine)

wockhardt limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. chemotherapy-induced nausea and vomiting [see dosage and administration (2)]  for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml; granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml - concentrate for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml excipient: citric acid monohydrate nitrogen sodium chloride sodium citrate water for injection - for the prevention & treatment of nausea & vomiting induced by cytotoxic chemotherapy (adults & children)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

apc pharmaceuticals & chemicals (europe) ltd - granisetron hydrochloride - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - granisetron hydrochloride - oral tablet - 2mg